TRVITrevi Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$49M
- 4.3% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$32M | −$30M | −$34M | −$52M | −$49M | 4.3% |
| Net income | −$34M | −$29M | −$29M | −$48M | −$43M | 11% |
| Operating cash flow | −$29M | −$28M | −$32M | −$38M | −$42M | 10% |
| Capex | — | $159K | $137K | $35K | $12K | 66% |
| Stock-based comp | $3M | $2M | $2M | $4M | $5M | 45% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $596K · 4
- Net
- −$596K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $4M | $15M | 649 | — |
| FY2024 | $3M | $5M | 213 | — |
| FY2023 | $2M | $1M | 69 | — |